Similar articles

• Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with type 2 diabetes mellitus.

  Rustemeijer C, Schouten JA, Voerman HJ, Hensgens HE, Donker AJ, Heine RJ. Rustemeijer C, et al. Diabetes Metab Res Rev. 2000 Mar-Apr;16(2):82-7. doi: 10.1002/(sici)1520-7560(200003/04)16:2<82::aid-dmrr89>3.0.co;2-g. Diabetes Metab Res Rev. 2000. PMID: 10751747 Clinical Trial.
• Predictors of change in low-density lipoprotein size during lipid-lowering treatment in type 2 diabetes.

  Wägner AM, Ordóñez-Llanos J, Jorba O, Pérez A. Wägner AM, et al. Metabolism. 2004 Nov;53(11):1516. doi: 10.1016/j.metabol.2004.07.005. Metabolism. 2004. PMID: 15558848 Clinical Trial. No abstract available.
• Normocholesterolaemic dysslipidaemia: is there a role for fibrates?

  Hamilton-Craig I. Hamilton-Craig I. Med J Aust. 2001 Jun 4;174(11):610; author reply 611. doi: 10.5694/j.1326-5377.2001.tb143459.x. Med J Aust. 2001. PMID: 11453341 No abstract available.
• [Overviews of fibrate].

  Tada N. Tada N. Nihon Rinsho. 2001 Mar;59 Suppl 3:609-17. Nihon Rinsho. 2001. PMID: 11347141 Review. Japanese. No abstract available.
• [Gemfibrozil: new aspects in clinical use].

  Tada N. Tada N. Nihon Rinsho. 2001 Mar;59 Suppl 3:625-30. Nihon Rinsho. 2001. PMID: 11347143 Review. Japanese. No abstract available.